TREATMENT OF REFRACTORY AND RELAPSED ADULT ACUTE-LEUKEMIA USING A UNIFORM CHEMOTHERAPY PROTOCOL

被引：9

作者：

MARTINO, R ^{[1
]}

BRUNET, S ^{[1
]}

SUREDA, A ^{[1
]}

MATEU, R ^{[1
]}

ALTES, A ^{[1
]}

DOMINGOALBOS, A ^{[1
]}

机构：

[1] HOSP SANTA CRUZ & SAN PABLO,DEPT HEMATOL,UNITAT HEMATOL CLIN,E-08025 BARCELONA,SPAIN

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 11卷 / 5-6期

关键词：

ADULT ACUTE LEUKEMIA; RELAPSED; REFRACTORY; CHEMOTHERAPY;

D O I：

10.3109/10428199309067931

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Twenty-nine adult patients with relapsed (21) or refractory (8) de novo acute leukemia (12 ALL and 17 ANLL) were treated with a remission-induction salvage chemotherapeutic protocol including vindesine, mitoxantrone, cyclophosphamide, intermediate-dose cytosine arabinoside, prednisolone and methotrexate. Ten of seventeen (59%) ANLL and 8/12 ALL (67%) achieved complete remission (CR). Seven of eight (86%) cases refractory to first-line remission-induction therapy (3/4 ANLL and 4/4 ALL) entered complete remission. The most frequent non-hematologic side effects were gastrointestinal. All patients experienced severe pancytopenia, with median times to recovery of granulocyte and platelet counts of 28 and 29 days, respectively. Nine of twenty-nine (31%) patients suffered febrile episodes of unknown origin and 13/29 (45%) suffered documented infections. Five patients (17%) died while aplastic, four from infection and one from cardiotoxicity. Four patients who entered CR were submitted to a bone marrow transplantation (BMT), two autologous and two allogeneic BMT. Sixteen of the 18 patients who entered CR relapsed, with a median remission duration of 3.5 +/- 2.9 months. Two patients remain in remission at 5+ and 17+ months. These results suggest that this protocol is an effective remission-induction salvage therapy for adult acute leukemias.

引用

页码：393 / 398

页数：6

共 26 条

[1]

Mayer R.J., Current chemotherapeutic treatment approaches to the management of previously untreated adults with de novo acute myelogenous leukemia, Sem. Oncol., 14, pp. 384-396, (1987)

[2]

Hoelzer D., Gale R.P., Acute lymphoblastic leukemia in adults: recent progress, future directions, Sem. Hematol., 24, pp. 27-33, (1987)

[3]

Bradstock K.F., Enno A., Hughes O., Et al., Treatment results in adolescent and adult acute lymphoblastic leukaemia using a uniform chemotherapy protocol, Leuk. Lymph., 4, pp. 317-324, (1991)

[4]

Bezwoda W.R., Seymour L., Ariad S., MacPhail P., Acute lymphoblastic leukaemia in adults. Prognostic factors and 10 year treatment results, Leuk. Lymph., 4, pp. 347-355, (1991)

[5]

Preisler H.D., Anderson K., Rai K., Et al., The frequency of long-term remission in patients with acute myelogenous leukemia treated with conventional maintenance chemotherapy. A study of 760 patients with a minimum follow-up time of 6 years, Br. J. Haematol., 71, pp. 189-194, (1989)

[6]

Herzig R.H., Wolff S.N., Lazarus H.M., Phillips G.L., Karanes C., Herzig G.P., High-dose cytosine arabinoside therapy for refractory leukemia, Blood, 62, pp. 361-369, (1983)

[7]

Van Prooijen H.C., Dekker A.W., Punt K., The use of intermediate dose cytosine arabinoside (IDAra-C) in the treatment of acute non-lymphocytic leukemia in relapse, Br. J. Haematol., 57, pp. 291-299, (1984)

[8]

Brito-Babapulle F., Catovsky D., Newland A.C., Goldman J.M., Gallon D.A.G., Treatment of acute myeloid leukemia with intermediate-dose cytosine arabinoside and mitoxantrone, Sem. Oncol., 14, pp. 51-52, (1987)

[9]

Hiddemann W., Kreutzmann H., Straif K., Et al., High dose cytarabine and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia, Blood, 69, pp. 744-749, (1987)

[10]

Walters R.S., Kantarjian H.M., Keating M.J., Et al., Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia, Cancer, 62, pp. 677-682, (1988)

← 1 2 3 →